Company Melisafarm Srl with Fiscal Code 8384500
recorded a turnover of 2024 of
229.737,
with a net profit of
14.081
and having an average number of employees of
2.
The company operates in the field of Comerţ cu amănuntul al produselor farmaceutice having the NACE code 4773.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Melisafarm Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
-
208.659
-
221.468
259.915
275.533
252.105
244.338
228.595
229.737
Total Income - EUR
-
211.365
-
237.270
261.564
284.493
260.363
252.165
235.657
238.876
Total Expenses - EUR
-
201.382
-
227.685
239.596
256.786
226.255
222.265
212.699
222.442
Gross Profit/Loss - EUR
-
9.983
-
9.585
21.968
27.706
34.108
29.901
22.958
16.434
Net Profit/Loss - EUR
-
9.098
-
7.370
19.379
25.061
31.587
27.457
20.674
14.081
Employees
-
4
-
3
4
2
2
2
2
2
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 1.1%, from 228.595 euro in the year 2023, to 229.737 euro in 2024.
The Net Profit decreased by -6.478 euro, from 20.674 euro in 2023, to 14.081 in the last year.
Check the financial reports for the company - Melisafarm Srl
Financial Rating - MELISAFARM SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Melisafarm Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Melisafarm Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Melisafarm Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
235.593 euro in 2024 which includes Inventories of
140.437 euro, Receivables of
83.923 euro and cash availability of
11.233 euro.
The company's Equity was valued at
107.217 euro, while total Liabilities amounted to
129.113 euro.
Equity increased by 14.081 euro, from 93.660 euro in 2023, to 107.217 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Melisafarm Srl